News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise? Todd Neale January 13, 2022
News Daily News Shorter Anticoagulation an Option for Young Patients With Provoked VTE Todd Neale January 11, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022
News Daily News Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S Caitlin E. Cox January 07, 2022
News Daily News Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study Yael L. Maxwell January 03, 2022
News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Daily News Black Patients With Chest Pain Differ From Whites, but Risks Are Similar Michael O'Riordan December 23, 2021
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021
News Daily News FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels Michael O'Riordan December 22, 2021
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Daily News Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions L.A. McKeown December 17, 2021
News Daily News Risk Factors Still Matter for Patients With Zero CAC Score: MESA Yael L. Maxwell December 14, 2021
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021